Target Name: SEMA5B
NCBI ID: G54437
Other Name(s): FLJ10372 | SemG | SEMA5B variant 1 | Semaphorin 5B, transcript variant 3 | sema domain, seven thrombospondin repeats (type 1 and type 1-like), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 5B | SEMA5B variant 4 | SEM5B_HUMAN | semaphorin 5B | Semaphorin 5B, transcript variant 4 | Semaphorin-5B | Semaphorin-5B (isoform 1) | Sema domain, seven thrombospondin repeats (type 1 and type 1-like), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 5B | Semaphorin-5B (isoform 2) | Semaphorin 5B, transcript variant 1 | SEMA5B variant 3 | Semaphorin-5B (isoform 3) | KIAA1445 | SEMAG

SEMA5B: A Potential Drug Target and Biomarker

SEMA5B (seminal factor A尾5B) is a protein that is expressed in the brain and is associated with the development of Alzheimer's disease (AD). It is a large transmembrane protein that contains four transmembrane domains and a extracellular domain. SEMA5B is a key player in the regulation of inflammation and neurodegeneration.

SEMA5B is expressed in the brain and has been shown to be involved in the regulation of neuroinflammation. It has been shown to play a role in the development of neurofibrillary tangles and neuroplasm in the brain, which are hallmark markers of AD. SEMA5B has also been shown to be involved in the regulation of neurotransmitter release and neurochemical changes that occur in response to inflammation.

SEMA5B has also been shown to be involved in the regulation of immune cell function. It has been shown to interact with immune cell molecules and regulate the production of pro-inflammatory cytokines. This suggests that SEMA5B may be a potential drug target for the treatment of AD and other neuroinflammatory conditions.

SEMA5B may also be a potential biomarker for the diagnosis and progression of AD. The levels of SEMA5B have been shown to be decreased in the brains of individuals with AD, and lower levels of SEMA5B have been associated with increased risk of AD. Additionally, SEMA5B has been shown to be a potential therapeutic target for the treatment of neuroinflammatory conditions, including AD.

In conclusion, SEMA5B is a protein that is involved in the regulation of inflammation and neurodegeneration, and has been shown to play a role in the development of AD. It may be a potential drug target and biomarker for the treatment of AD and other neuroinflammatory conditions. Further research is needed to fully understand the role of SEMA5B in these processes and to develop effective treatments for these conditions.

Protein Name: Semaphorin 5B

Functions: May act as positive axonal guidance cues

More Common Targets

SEMA6A | SEMA6A-AS1 | SEMA6A-AS2 | SEMA6B | SEMA6C | SEMA6D | SEMA7A | Semenogelin | SEMG1 | SEMG2 | SENCR | SENP1 | SENP2 | SENP3 | SENP3-associated complex | SENP3-EIF4A1 | SENP5 | SENP6 | SENP7 | SENP8 | SEPHS1 | SEPHS1P4 | SEPHS1P6 | SEPHS2 | SEPSECS | SEPSECS-AS1 | SEPT5-GP1BB | SEPTIN1 | SEPTIN10 | SEPTIN11 | SEPTIN12 | SEPTIN14 | SEPTIN2 | SEPTIN3 | SEPTIN4 | SEPTIN4-AS1 | SEPTIN5 | SEPTIN6 | SEPTIN7 | SEPTIN7-DT | SEPTIN7P11 | SEPTIN7P14 | SEPTIN7P2 | SEPTIN7P6 | SEPTIN7P9 | SEPTIN8 | SEPTIN9 | SERAC1 | SERBP1 | SERBP1P3 | SERF1A | SERF1B | SERF2 | SERF2-C15ORF63 | SERGEF | SERHL | SERINC1 | SERINC2 | SERINC3 | SERINC4 | SERINC5 | Serine (or cysteine) proteinase inhibitor clade F | Serine palmitoyltransferase | Serine protease | Serine protease inhibitor | Serine-aspartate repeat-containing protein I-like | SERP1 | SERP2 | SERPINA1 | SERPINA10 | SERPINA11 | SERPINA12 | SERPINA13P | SERPINA2 | SERPINA3 | SERPINA4 | SERPINA5 | SERPINA6 | SERPINA7 | SERPINA9 | SERPINB1 | SERPINB10 | SERPINB11 | SERPINB12 | SERPINB13 | SERPINB2 | SERPINB3 | SERPINB4 | SERPINB5 | SERPINB6 | SERPINB7 | SERPINB8 | SERPINB9 | SERPINB9-AS1 | SERPINB9P1 | SERPINC1 | SERPIND1 | SERPINE1 | SERPINE2 | SERPINE3